Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy

Y. Miyaji, T. Tsushima, Y. Nasu, M. Noda, T. Murakami, S. Kaku, Shin Ebara, H. Ohmori

Research output: Contribution to journalArticle

Abstract

Interferon-α (IFN-α) was prophylactically administered to the patients with high-stage renal cell cancer after radical nephrectomy. Seventeen patients who were at high risk for recurrence of disease received 500 x 104 units of IFN-α, 2 or 3 times per week for 2 years. Median followup was 21.5 months. Of the patients 4 (23.5%) revealed pulmonary metastasis with or without local recurrence. The administration of IFN-α for 2 patients was discontinued because of side effects. One patient showing pulmonary metastasis has survived, 2 died of cancer and 1 of an unrelated cause. Immunological changes were analyzed by measurement of peripheral blood lymphocyte subsets. Two-color flow cytometry was used to evaluate the lymphocyte subsets consisting of suppressor T lymphocytes (CD8+ CD11b+), cytotoxic T lymphocytes (CD8+ CD11b-), helper T lymphocytes (CD4+ CD45 RA+), suppressor inducer T lymphocytes (CD4+ CD45 RA-), natural killer cells (CD3- CD56+), natural killer T cells (CD3+ CD56+), activated CD8 positive cells (CD8+ HLA-DR+) and activated CD4 positive cells (CD4+ HLA DR+). The number of suppressor T lymphocytes and activated CD8 positive cells increased in the recurrent cases. In contrast, suppressor T lymphocytes gradually decreased after IFN-α treatment, and no evidence of cancer was found in the remaining cases.

Original languageEnglish
Pages (from-to)1201-1207
Number of pages7
JournalBiotherapy
Volume10
Issue number9
Publication statusPublished - Dec 2 1996

Keywords

  • Adjuvant therapy
  • Interferon-α
  • Lymphocyte subset
  • Renal cell cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy'. Together they form a unique fingerprint.

  • Cite this

    Miyaji, Y., Tsushima, T., Nasu, Y., Noda, M., Murakami, T., Kaku, S., Ebara, S., & Ohmori, H. (1996). Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy. Biotherapy, 10(9), 1201-1207.